Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-18

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will test whether the combination of cisplatin, nivolumab, and temozolomide is an effective treatment for in people with advanced and/or metastatic colorectal cancer that is mismatch repair-proficient (MMR-proficient). The researchers will also look at how safe the study drug combination is in participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

NCT03879811

Colorectal Cancer

WITHDRAWN PHASE2

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

NCT05328908

Colorectal Neoplasms

TERMINATED PHASE3

Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

NCT03712943

Colorectal Cancer Metastatic Colorectal Cancer Colon Cancer

COMPLETED PHASE1

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

NCT04166435

Colorectal Cancer

COMPLETED PHASE2

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

NCT03377361

Colorectal Cancer Colorectal Tumors Colorectal Carcinoma +1 more

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This will be a two-stage design, single arm, phase II study.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

temozolomide, cisplatin and nivolumab

Subjects will receive oral TMZ at 150-200 mg/m2 day 1 to 5 every 4 weeks, cisplatin via IV infusion at 40 mg/m2 every two weeks (Q2W), and nivolumab via IV infusion at 480 mg every four weeks (Q4W).

Group Type EXPERIMENTAL

Temozolomide (TMZ)

Intervention Type DRUG

TMZ 150 mg/m2 Day 1 - 5 Q4W PO Cycle 1

TMZ 200 mg/m2 Day 1 - 5 Q4W PO Cycle 2 +

Cisplatin

Intervention Type DRUG

Cisplatin 40 mg/m2 Q2W IV infusion Cycle 1 +

Nivolumab

Intervention Type DRUG

Nivolumab 480 mg Q4W IV infusion Cycle 1 +

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Temozolomide (TMZ)

TMZ 150 mg/m2 Day 1 - 5 Q4W PO Cycle 1

TMZ 200 mg/m2 Day 1 - 5 Q4W PO Cycle 2 +

Intervention Type DRUG

Cisplatin

Cisplatin 40 mg/m2 Q2W IV infusion Cycle 1 +

Intervention Type DRUG

Nivolumab

Nivolumab 480 mg Q4W IV infusion Cycle 1 +

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject or legally authorized representative is willing and able to provide written informed consent/assent for the trial.
* Histologically- or cytologically- confirmed colorectal adenocarcinoma.
* Locally advanced unresectable or metastatic CRC.
* Undergone testing for MSI/dMMR and determined to be MSS or MMR proficient.
* Undergone testing for BRAF and POLE and determined to be wild type.
* Subjects must be refractory to, or intolerant of, at least 2 lines of standard chemotherapy, according to NCCN guidelines for patients eligible for intensive therapy, or have received prior FOLFOXIRI. Patients are considered refractory if progressed within 3 months of last dose, or within 6 months of completing adjuvant FOLFOX/CAPEOX. At a minimum, such therapies should include oxaliplatin, irinotecan and a fluoropyrimidine.
* At least one index lesion which is measurable based on RECIST 1.1.
* Be ≥ 18 years of age on day of signing informed consent.
* Consent for use of archival tissue and blood draws for research purposes.
* Have an ECOG performance status of 0 or 1.
* Demonstrate adequate organ function as defined in Table 6.1, all screening labs should be performed within 28 days of treatment initiation.
* Adequate organ function, defined as:

* Absolute Neutrophil Count ≥ 1,500/mcL.
* Platelet count ≥ 100,000/mcL.
* Serum creatinine ≤ 1.5 x ULN or CrCl ≥60 mL/min for subjects with creatinine levels \>1.5 ULN.
* WBC ≥ 2000/μL
* Hemoglobin ≥ 9.0 g/dL
* AST and ALT ≤ 2.5 × ULN or ≤ 5 × ULN for subjects with liver metastases.
* Bilirubin ≤ 1.5 × ULN or Direct bilirubin ≤ ULN for subjects with bilirubin levels \>1.5
* INR/PT and PTT ≤1.5 X ULN unless on anticoagulant therapy and PT/PTT within therapeutic range.

aCreatinine clearance should be calculated per institutional standard.

* Adequate method of contraception.

Exclusion Criteria

* Subject is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.
* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (\>10 mg/day prednisone, or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Inhaled or topical steroids are permitted in the absence of active autoimmune disease
* Prior chemotherapy, targeted small molecule therapy, or biological therapy, within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent (exc. alopecia).
* If subject received major surgery, they must have recovered adequately prior to starting therapy.
* Has a known additional malignancy that is progressing or requires active treatment.
* Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment.
* Has an active, known or suspected autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy, type 1 diabetes mellitus are permitted. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study.
* Has an active infection requiring systemic therapy
* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or it is not in the best interest of the subject to participate, in the opinion of the treating investigator.
* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 5 months for females, 7 months for males after the last dose of trial treatment.
* Prior anti-PD-1, anti-PDL-1, anti-PDL-2, anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
* Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
* Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected).
* Has received a live vaccine within 30 days prior to the first dose of trial treatment.
* Subject is a prisoners, or compulsory detained

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No